Literature DB >> 20425415

The role of gemtuzumab ozogamicin in combination chemotherapy regimens for primary resistant or relapsed acute myeloid leukemia.

Hien K Duong1, Matt Kalaycio.   

Abstract

Entities:  

Year:  2009        PMID： 20425415     DOI： 10.1007/s11899-009-0008-3

Source DB:  PubMed          Journal:  Curr Hematol Malig Rep        ISSN： 1558-8211            Impact factor:   3.952


× No keyword cloud information.
  4 in total

1.  Incidence and outcome of hepatic veno-occlusive disease after blood or marrow transplantation: a prospective cohort study of the European Group for Blood and Marrow Transplantation. European Group for Blood and Marrow Transplantation Chronic Leukemia Working Party.

Authors:  E Carreras; H Bertz; W Arcese; J P Vernant; J F Tomás; H Hagglund; G Bandini; H Esperou; J Russell; J de la Rubia; G Di Girolamo; H Demuynck; O Hartmann; J Clausen; T Ruutu; V Leblond; A Iriondo; A Bosi; I Ben-Bassat; V Koza; A Gratwohl; J F Apperley
Journal:  Blood       Date:  1998-11-15       Impact factor: 22.113

2.  Retrospective multivariate analysis of hepatic veno-occlusive disease after blood or marrow transplantation: possible beneficial use of low molecular weight heparin.

Authors:  M Simon; T Hahn; L A Ford; B Anderson; D Swinnich; M R Baer; B Bambach; S H Bernstein; Z P Bernstein; M S Czuczman; J L Slack; M Wetzler; G Herzig; J Schriber; P L McCarthy
Journal:  Bone Marrow Transplant       Date:  2001-03       Impact factor: 5.483

3.  Prevention of hepatic veno-occlusive disease after bone marrow transplantation by continuous infusion of low-dose heparin: a prospective, randomized trial.

Authors:  M Attal; F Huguet; H Rubie; A Huynh; J P Charlet; J L Payen; J J Voigt; P Brousset; J Selves; C Muller
Journal:  Blood       Date:  1992-06-01       Impact factor: 22.113

Review 4.  Treatment of refractory and relapsed acute myelogenous leukemia.

Authors:  Slobodan Stanisic; Matt Kalaycio
Journal:  Expert Rev Anticancer Ther       Date:  2002-06       Impact factor: 4.512
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.